The Korean heart rhythm society's 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: Korean heart rhythm society

Korean Circulation Journal

Volumn 45, Issue 1, 2015, Pages 9-19

  Jung, Byung Chun ^a   Kim, Nam Ho ^b   Nam, Gi Byung ^c   Park, Hyung Wook ^d   On, Young Keun ^e   Lee, Young Soo ^f   Lim, Hong Euy ^g   Joung, Boyoung ^h   Cha, Tae Joon ⁱ   Hwang, Gyo Seung ^j   Oh, Seil ^k   Kim, June Soo ^e  

^a Daegu Fatima Hospital   (South Korea)

^b Wonkwang University Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Catholic University of Daegu   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h Yonsei University   (South Korea)

ⁱ Kosin University   (South Korea)

^j Ajou University Medical CentSuwon   (South Korea)

^k Seoul National University Hospital   (South Korea)

more..

Author keywords

Anticoagulant; Antithrombotic agent; Atrial fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SOUTH KOREA; THROMBOEMBOLISM;

EID: 84921867375     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2015.45.1.9     Document Type: Review

References (25)

1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
2. Park JM, Hong KS, Han SW, et al. Focused update on primary stroke prevention in patients with atrial fibrillation in Korean Clinical Practice Guidelines for Stroke. Korean J Stroke 2012;14:106-15.
3. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
6. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
7. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
8. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
9. Clinical Research Center for Stroke. Primary prevention of stroke. In: Writing group of clinical practice guideline for stroke, editor. Clinical Practice Guideline for Stroke. 1st ed. Seoul: Clinical Research Center for Stroke; 2009. p. 34-5.
10. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-429.
11. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36.
12. Ogawa S, Aonuma K, Tse HF, et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm 2013;29:190-200.
13. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104.
14. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
15. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093-100.
16. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955-62.
17. Bang OY, Hong KS, Heo JH, et al. New oral anticoagulants may be particularly useful for Asian stroke patients. J Stroke 2014;16:73-80.
18. ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-78.
19. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
20. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
21. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8.
22. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
23. Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44:1891-6.
24. Wong KS, Hu DY, Oomman A, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014;45: 1739-47.
25. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007;50:309-15.